Foghorn Therapeutics Valuation
| FHTX Stock | USD 4.31 0.11 2.62% |
At this time, the firm appears to be undervalued. Foghorn Therapeutics shows a prevailing Real Value of $6.19 per share. The current price of the firm is $4.31. Our model computes the value of Foghorn Therapeutics from reviewing the firm fundamentals such as Operating Margin of (3.05) %, shares owned by insiders of 18.98 %, and Shares Outstanding of 55.59 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Foghorn Therapeutics' valuation include:
Price Book 10.707 | Enterprise Value | Enterprise Value Ebitda (1.21) | Price Sales 9.3908 | Enterprise Value Revenue 0.2024 |
Undervalued
Today
Please note that Foghorn Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Foghorn Therapeutics is based on 3 months time horizon. Increasing Foghorn Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Foghorn Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Foghorn Stock. However, Foghorn Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.31 | Real 6.19 | Target 12.0 | Hype 4.13 |
The intrinsic value of Foghorn Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Foghorn Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Foghorn Therapeutics helps investors to forecast how Foghorn stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Foghorn Therapeutics more accurately as focusing exclusively on Foghorn Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Foghorn Therapeutics' intrinsic value based on its ongoing forecasts of Foghorn Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Foghorn Therapeutics' closest peers.
Foghorn Therapeutics Cash |
|
Foghorn Valuation Trend
Analysing the historical paterns of Foghorn Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Foghorn Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Foghorn Therapeutics Total Value Analysis
Foghorn Therapeutics is currently anticipated to have valuation of 5.16 M with market capitalization of 239.61 M, debt of 45.07 M, and cash on hands of 373.5 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Foghorn Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.16 M | 239.61 M | 45.07 M | 373.5 M |
Foghorn Therapeutics Investor Information
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.9. Foghorn Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Foghorn Therapeutics' liquidity, profitability, solvency, and operating efficiency, Foghorn Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Foghorn Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Foghorn Therapeutics has an asset utilization ratio of 11.95 percent. This suggests that the Company is making $0.12 for each dollar of assets. An increasing asset utilization means that Foghorn Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Foghorn Therapeutics Ownership Allocation
Foghorn Therapeutics holds a total of 55.59 Million outstanding shares. The majority of Foghorn Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Foghorn Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Foghorn Therapeutics. Please pay attention to any change in the institutional holdings of Foghorn Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Foghorn Therapeutics Profitability Analysis
The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (82.3 M).About Foghorn Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Foghorn Therapeutics. We calculate exposure to Foghorn Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Foghorn Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -68 M | -64.6 M | |
| Pretax Profit Margin | (2.48) | (2.61) | |
| Operating Profit Margin | (2.84) | (2.99) | |
| Net Loss | (2.59) | (2.72) | |
| Gross Profit Margin | (1.99) | (2.09) |
Foghorn Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 42 M |
Foghorn Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Foghorn Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Foghorn we look at many different elements of the entity such as Foghorn's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Foghorn Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Foghorn Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Foghorn Therapeutics' worth.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.